Analysis of "CDKs 4/6" efficacy in combination with hormone treatment in HR+ HER2 negative breast cancer according to PAM50 intrinsic subtype and immuno proliferation biomarkers
CDK-PREDICT
Biomarker Program
Efficacy analysis of CDK4/6 inhibitors in combination with endocrine treatment in luminal breast cancer according to the intrinsic subtype and immune markers
Phase 0
Status
Recruiting
Tumour subtype:
HR+
Scenario
Localmente avanzado o metastático
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Eva Ciruelos Gil, MD, PhD (Hospital Universitario 12 de octubre de Madrid y Hospital Universitario HM CIOCC, Madrid)
